Loading…
← CockpitCompetitor Analysis › 347850.KS D&D Pharmatech Co., Ltd.Open in the cockpit ↗

D&D Pharmatech Co., Ltd.347850.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.

Momentum weak 20
Mkt cap
$1.22B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$16.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-46.5 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Close · KRW₩35,800
1D-1.9%
1W-16.7%
1M-11.8%
3M-41.7%
6M-48.6%
YTD-61.0%
1Y-52.1%
ATR %9.4%
52w lowhigh69.3% off high

What D&D Pharmatech does

Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.

Earns little from sales of its own; its value comes from licensing peptide candidates to bigger partners for upfront and milestone payments, and from equity stakes in those partners, notably Metsera, a US obesity-drug developer built partly on its licensed assets.

Products and services

  • DD01 (GLP-1/glucagon dual agonist, MASH)
  • Obesity/GLP-1 pipeline
  • Neurodegenerative-disease pipeline

Customers

  • Global pharma licensing partners (Metsera and othe

Where it sits in the supply chain

  • Biotechnology
  • Peptide-based drug development
  • Global pharma licensing

What could go right

  • GLP-1/obesity licensing deals and milestones
  • DD01 clinical progress

What could go wrong

  • Clinical-trial failure risk
  • Reliance on partner licensing milestones

Moat: narrow (IP / patents). Peptide-delivery platform behind several GLP-1 obesity candidates already licensed to global partners.

Headquarters: Seoul, South Korea · Founded: 2014 · Employees: 22

Named competitors

D&D Pharmatech at a glance

Size D&D Pharmatech (347850.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.22B, the 209th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩35,800 on 18 Nov 2026.

Performance Over six months the shares fell 48.6%, against -20.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 76.8% over the last twelve months (peer median +7.6%); the operating margin is -2,324.3% (peer median -2.1%).

Valuation It trades at 818.8× enterprise value to sales against a peer median of 8.6× (most expensive of 18).

Capital Return on invested capital runs 46.5 points below its cost of capital (7.9% WACC).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 81347850.KS 52
Six months, rebased to 100: D&D Pharmatech against the median of its 20 peers (local-currency closes).

D&D Pharmatech financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.94B₩4.30B₩11.4B₩18.7B₩611M
Revenue growth—-62%-39%+2,959%—
Gross profit-₩3.77B-₩1.23B₩5.91B₩14.2B-₩13.1B
EBITDA-₩39.3B-₩28.5B-₩19.5B-₩9.06B-₩54.9B
Net income-₩32.9B-₩23.6B-₩28.6B₩3.93B-₩136B
Free cash flow-₩26.9B-₩21.2B-₩22.2B-₩9.16B-₩53.8B
Capital expenditure₩206M₩64.4M₩416M₩45.2M₩719M
Total debt₩118B₩6.24B₩9.78B₩8.13B₩27.2B

Quarterly statements and history in the cockpit →

D&D Pharmatech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%IDIA300026HROW2616300006AVLN2493GPCR000950688321GHRS688443300204NKTR6855AMPH000989002332301263347850.KS6-month return →1-month return →
Up and to the right = strong over both horizons. D&D Pharmatech is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×IDIA300026HROW26166884433002046855347850.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. D&D Pharmatech is the large dot.

D&D Pharmatech competitors and peer comparison

Head to head with its named competitors (347850.KS vs 128940.KS vs NOVO-B.CO)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
D&D Pharmatech 347850.KS$1.22B-49%-77%-2,324%818.8×n/a
HanmiPharm 128940.KS$3.95B-2%+14%16%3.3×4.7%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%

How D&D Pharmatech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

D&D Pharmatech against its 20 peers (data as of 18 Nov 2026)
Measure347850.KSPeer medianRank in peer set
1-month return-11.8%-5.4%6th lowest of 21
6-month return-48.6%-20.6%3rd lowest of 21
Distance from 52-week high-69.3%-41.7%2nd lowest of 21
Revenue growth (TTM)-76.8%+7.6%lowest of 18
Operating margin-2,324.3%-2.1%lowest of 18
EV / Sales818.8×8.6×most expensive of 18
ROIC minus cost of capital-46.5 pp-6.1 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a

Questions

Who are D&D Pharmatech's main competitors?
Named competitors: HanmiPharm (128940.KS), Novo Nordisk (NOVO-B.CO). The cockpit's measured peer set (industry) also includes Idorsia (IDIA.SW), Tianjin Chase Sun Pharmaceutical (300026.SZ), Harrow (HROW), CStone Pharmaceuticals (2616.HK), Chongqing Lummy Pharmaceutical (300006.SZ), Avalyn Pharma (AVLN).
Is D&D Pharmatech expensive compared with its peers?
On ev / sales it trades at 818.8× against a peer median of 8.6×, most expensive of 18 in its peer set.
How has D&D Pharmatech stock performed?
Over six months to 18 Nov 2026 the shares returned -48.6% against -20.6% for the median peer; over one year -52.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.